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Introduction 
Asthma is a common long term hypersensitivity and 
inflammatory disease and is described by reversible 
airflow obstruction, bronchospasm and other 
variable recurring symptoms.1 Various approaches 
can be used as treatments of respiratory diseases like 
asthma, however, the pulmonary drug delivery route 
represents an appealing and encouraging way to 
localize drug delivery.2,3 The main advantages of the 
pulmonary administration in comparison with other 
drug delivery routes are related to the large alveolar 
surface area and extensive vascularization which is 
suitable for drug absorption.4,5 Salbutamol is one of 
a group of medicines called bronchodilators which 
helps to open up the airways and so relieve chest 
tightness and cough resulting more easily breathe. 
Salbutamol stimulates receptors in the lung called 
beta 2 receptors and causes the muscles in the 
airways to relax and makes it easier to breathe.6 
Inhaling the medicine allows it to act directly in the 
lung where it is most needed and among the 
pulmonary drug delivery systems, metered dose 
inhalers (MDIs) are undoubtedly the most 
widespread and popular used devices for pulmonary 
delivery.7 MDIs developed in 1956 and are the most 
widely used devices for aerosol therapy and used by 
over 70 million worldwide. An MDI consists of a 
canister holding suspension or solution containing 
drug and surfactants, propellant and lubricants. 
MDIs are easy to use, handy and relatively low-cost 
which designed for delivery of multiple drug doses 
in a sequence. The particles aerodynamic diameter 
should be lower than 5 µm to effective particle 
deposit in the lower airways. The size of delivered 
particles by MDIs is influenced by a range of factors, 
such as: inside pressure of the canister, propellant’s 
physicochemical properties, type and concentration 
of drug, as well as design of valve and delivery 
outlet.8,9 Some physicians are reluctant to accept that 
generic salbutamol device is really as effective as 
the reference brand. To clarify this issue, a few 
studies have been carried out in different countries 
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by universities to not only test the domestic products 
but also to encourage the physicians to choose more 
cost benefit way of treatment if the domestics 
products passed from their examinations.10-15 
Anecdotally, there is no evidence to support that 
generic inhaled salbutamol is inferior to the branded 
product. Therefore, in vitro aerosolization efficiency 
analysis of domestic products are necessary to show 
that generic Salbutamol MDIs possess similar 
aerosolization efficiency to the reference brand 
ones.16 This study aimed to assess whether a 
commonly prescribed generic Salbutamol MDIs (B 
and C) are as similar as (A) as a reference brand in 
the case of aerosolization efficiency.  
 
Materials and Methods 
Materials 
Salbutamol sulphate was provided from Zahravi 
Pharmaceutical Company (Tabriz, Iran). HPLC 
grade Methanol was obtained from Duksan 
Chemicals (Kyungkido, Korea). Tween® and 
Ethanol 80 were purchased from Merck Chemicals 
(Darmstadt, Germany) and JATA (Arak, Iran) 
Companies, respectively.  
 
In vitro aerosolization assessment  
The aerodynamic particle size distribution of three 
Salbutamol MDIs was studied according to the USP 
monograph (using USP apparatus 6) by next 
generation impactor (NGI) (Copley Scientific, 
Nottingham, UK).17 To connect the NGI device to 
MDI the induction port was employed. To confirm 
an efficient particle capture and inhibit inter-stage 
losses caused by particle bounce, the surface of each 
stage was coated with Tween® 80.  For this aim, the 
NGI’s collection cups were soaked into ethanolic 
solution of Tween® 80 (1 %) and placed under the 
hood until the complete ethanol evaporation. The 
impactor lid was closed with the sealed body and the 
handle was used to lock the impactor together. The 
induction port was linked to the first NGI’s stage. 
The flow rate was calibrated by a flow meter (DFM 
2000, Copley Scientific, Nottingham, UK) and fixed 
at 30 L/min. After checking of the assembly and 
ensuring of airtight, as well as shaking up and down 
for ten seconds, A, B and C MDIs had been placed 
in into the mouthpiece attached to the USP induction 
port. The vacuum pump (HCP5, Copley Scientific, 
Nottingham, UK) was turned on and let it to increase 
to the steady flow rate (30 L/min). Finally, the dose 
was released for two times with the five seconds 
interval and the pump was turn off after five seconds 
of the second actuation. After two doses firing into 
the apparatus, the throat and stages were washed 
with 15 mL of methanol: PBS pH= 4 (40: 60, v/v) 
solution, and the amount of Salbutamol was 
evaluated using our developed and validated HPLC 
method for six times and the results are shown as 
averages ± standard deviations. Fine particle dose 
(FPD), fine particle fraction (FPF), geometric 
standard deviation (GSD) and mass median 
aerodynamic diameter (MMAD) indexes were 
calculated using the Copley Inhaler Testing Data 
Analysis Software (CITDAS, version 3.10). The 
MMAD is expressed as the diameter at which 50 % 
of the particles (by mass) are larger and 50 % are 
smaller. Whereas the FPF and FPD are defined as 
the fraction and doses of drugs carried in particles 
with a diameter of <5µm.18,19  
 
High performance liquid chromatography (HPLC) 
analysis 
The amount of Salbutamol was evaluated using a 
reversed-phase HPLC system (Knauer apparatus, 
Germany) involved of 1000 and 2600 tunable HPLC 
pump and absorbance detector models. Salbutamol 
was separated at room temperature by a C18 column 
(4.6 mm×150 mm, 10 µm, 125 A◦) (Germany). The 
mobile phase was consisted of methanol and PBS 
pH=4 (40:60) and flow rate was set at 1 mL/min. 
The sample injection volume and detecting 
wavelength were set 20 µL and 254 nm, 
respectively. The retention time was about 6 min and 
the area under the curve of Salbutamol peak was 
computed by apparatus software (ChromGate 
Client/Server, version 3.1.7) (Responses were linear 
in the range of 1–20 µg/mL, r2=0.9982).   
 
Statistical analysis 
Data are shown as a mean ± standard deviation (SD). 
Statistical analysis was done using a one-way 
analysis of variance (ANOVA) using a Tukey-
Kramer HSD test by SPSS software (version 13.0, 
Chicago, IL, USA). A P value <0.05 was considered 
as statistically signiﬁcant.  
 
Results and Discussion 
The clinical effects of inhaled drugs used for asthma 
are determined by the total amount of deposited drug 
in the lungs and its distribution in the airways with 
different sizes. MDIs are the traditional and 
recommended means of delivering inhaled drugs 
used for asthma such as Salbutamol due to the easy 
to use and portability for the delivery of any dose 
especially in children.20-22 In 1997, some 
pharmaceutical companies tried to develop and 
manufacture inhalers and formed an association to 
progress a new impactor which specifically 
designed for testing pharmaceutical inhalers by 
using the new and modern designed theory. 
Flexibility of use and high productivity make NGIs 
the most popular analysis machine among many 
inhaler research laboratories. Subsequently, NGIs 
were accepted into the United States Pharmacopeia 
as Apparatus 5 and 6 in 2005 and into the European 
Pharmacopeia as Apparatus E in 2000. The in vitro 
parameters which should be measured for each MDI 
including FPF, FPD, GSD and MMAD are exhibited 
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in Table 1. The details of Salbutamol deposition in 
different stages of NGI are presented in Figure 1. 
FPF and FPD values show the fraction and amount 
of Salbutamol particles reach to the lower 
respiratory tract. The higher values indicate the 
better aerosolization performance of MDIs. 
The results of FPF and FPD values indicated that the 
aerosolization efficacy of reference Salbutamol 
MDI was higher than B and C MDIs, however, the 
differences were not significant (P>0.05). GSD 
displays the aerodynamic size distribution of 
aerosolized particles through the MDIs which 
measured from drug deposition in the various stages 
of NGI. The lower GSD value specifies the narrower 
size distribution which warranties predictable and 
reproducible therapeutic outcomes. As shown in 
Table 1, C MDI showed better GSD values than A 
and B MDIs. The Ideal MMAD value for pulmonary 
drug delivery systems is considered between 1 to 5 
µm. In the case of MMAD results, like previous 
parameters, although A MDI showed the better 
results in comparison with other brands, the 
differences were not significant.
 
  
 
Table 1. Aerosolization efficiency indexes of A, B and C CMDIs (4 batches) analyzed by the NGI (data presented 
as mean ± SD, n= 3). 
Brand FPDa (µg) FPFb (%) MMADc (µm) GSDd 
A (1) 30.85 ± 5.35 34.14 ± 1.22 3.51 ± 0.10 2.77 ± 0.07 
A (2) 39.50 ± 17.14 39.73 ± 12.63 2.19 ± 1.14 2.75 ± 0.88 
A (3) 21.86 ± 1.25 24.19 ± 0.56 3.07 ± 0.96 NA 
A (4) 49.03 ± 10.78 56.14 ± 24.66 1.87 ± 0.87 NA 
B (1) 57.13 ± 29.28 52.01 ± 18.50 2.66 ± 0.56 2.27 ± 0.21 
B (2) 20.83 ± 2.16 24.34 ± 1.70 2.50 ± 0.63 NA 
B (3) 33.18 ± 5.22 33.17 ± 5.33 2.85 ± 0.53 3.39 ± 0.26 
B (4) 24.77 ± 3.03 26.84 ± 5.87 4.78 ± 0.92 3.05 ± 0.99 
C (1) 30.85 ± 5.35 34.14 ± 1.22 3.51 ± 0.10 2.77 ± 0.07 
C (2) 39.50 ± 17.14 39.73 ± 12.63 2.19 ± 1.14 2.75 ± 0.88 
C (3) 21.86 ± 1.25 24.19 ± 0.56 3.07 ± 0.96 NA 
C (4) 49.03 ± 10.78 56.14 ± 24.66 1.87 ± 0.87 NA 
aFine particle dose (FPD)  
bFine particle fraction (FPF)  
cMass median aerodynamic diameter (MMAD) 
dGeometric standard deviation (GSD)  
eNot available (Could not be measured) 
 
 
 
Figure 1. The aerosolization indexes; a) fine particle dose (FPD), b) fine particle fraction (FPF), c) geometric 
standard deviation (GSD), and d) mass median aerodynamic diameter (MMAD) of A, B and  C MDIs (data presented 
as mean ± standard deviation, n= 4).
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Conclusion 
The use of aerosol therapy for pulmonary drug 
delivery in lung diseases has increased considerably 
in recent years. Confirming that generic MDIs 
deliver the same active compound in equivalent 
amounts to the reference brand product and the 
absence of any difference in efficacy is critical. This 
study provides in vitro data to show that generic 
salbutamol is equivalent in efficacy to the reference 
brand product. Due to the high prices, patients using 
branded MDIs could have converted to the generic 
product and save many money per year. For the 
future in vivo assessment on patients was suggested 
when converting patients from the branded to the 
generic product. Unfortunately, data is not available 
showing that different generic products are 
pharmacologically equivalent to the branded 
product and this should help convince physicians at 
least, that the generic product can be prescribed with 
assurance. 
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